Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pharmaceutical Highlights: Alnylam Pharmaceuticals, Inc. (ALNY) & Synta Pharmaceuticals Corp. (SNTA)’s HDC Platform, Inovio Pharmaceuticals Inc (INO)’s Worth

Editor’s Note: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Inovio Pharmaceuticals Inc (NYSEMKT:INO)

Synta (SNTA) Launches HDC Platform (
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced the launch of its Hsp90-inhibitor Drug Conjugate (HDC) platform, which leverages the Company’s expertise in chaperone biology and medicinal chemistry to create a new class of anti-cancer therapies. Current oncology therapeutics generally fall into two categories: cytotoxic agents and molecularly targeted therapies. Cytotoxic agents are often broadly active, but have the disadvantage of high toxicity caused by damage to normal cells, which limits their utility.

What Is Inovio Worth After The Roche Deal? (Seeking Alpha)
Inovio Pharmaceuticals Inc (NYSEMKT:INO) just closed a $422 million deal with Roche Pharmaceuticals changing the whole perception of the company and its technology. The deal covers only two of Inovio’s current pipeline of nine drugs. The drugs included in the partnership agreement are INO-5150 for prostate cancer, and INO-1800 for Hepatitis B. This deal fundamentally revalues Inovio. One of the largest pharmaceutical companies in the world feels that Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s DNA vaccine technology, and electroporation technology is worth investing over 400 million dollars in.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals Management Presents at Morgan Stanley Healthcare Conference (Transcript) (Seeking Alpha)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Morgan Stanley Healthcare Conference Call September 10, 2013 11:00 AM ET [No presentation session for this event.]

Top Stocks: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Penn Virginia Corporation (NYSE:PVA), Walter Energy, Inc. (NYSE:WLT), Fusion-IO, Inc.(NYSE:FIO) (TechSonian)
Value Penny Stocks issues a special report on Inovio Pharmaceuticals Inc (NYSEMKT:INO), Penn Virginia Corporation, Walter Energy, Inc., Fusion-IO, Inc.. Inovio Pharmaceuticals Inc shares increased 14.86% to $2.55. Roche and Inovio Pharmaceuticals, Inc. on Sept. 10 announced that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio’s highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated robust T-cell responses in animal models.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!